Sunovion har också Latuda

Läkemedelsföretaget Sunovion skall starta FAS II studier med antipsykotikat SEP-363856 mot schizofreni och psykoser vid Parkinsons sjukdom.

Det nya antipsykotikat verkar ej genom blockering av dopmin-2-receptorer utan effekten är okänd.

Man tror att den kan stimulera 5-HT1A and TAAR1 receptorer samt att den också kan ha effekt mot negativa symptom. 

Läs mer hos Businesswire.

Kommentar  
En större studie har gjorts på fler patienter och effekt kunde påvisas.
"If these results are confirmed, this will be big, big news,” says Jeffrey Lieberman, a psychiatrist at Columbia University.

https://www.sciencemag.org/news/2020/04/experimental-schizophrenia-drug-could-reduce-long-neglected-symptoms
Although the PANSS total scores were similar in the SEP-363856 group (n = 120) and the placebo group (n = 125) at baseline, analysis indicated a significantly greater reduction for SEP-363856 by week 4 on the total score (–17.2 vs. –9.7; P = .001), the positive subscale score (–5.5 vs. –3.9; P = .019), the negative subscale score (–3.1 vs. –1.6; P = .008) and the general psychopathology subscale score (–9.0 vs. –4.7; P < .001).


https://www.healio.com/psychiatry/schizophrenia/news/online/%7B9f8fa3dd-7071-4c9c-9037-aed8c5f992d9%7D/novel-psychotropic-agent-improves-symptoms-in-schizophrenia
The SEP 361-201 study was a four-week, double-blind, placebo-controlled trial involving 245 adults hospitalized with an acute exacerbation of schizophrenia. They were randomly allocated to SEP-363856 (50 mg or 75mg once daily) or placebo.

After four weeks, patients taking SEP-363856 showed statistically significant and clinically meaningful improvement in the Positive and Negative Syndrome Scale (PANSS) total score (primary outcome) compared with placebo (-17.2 vs. -9.7; P=0.001, effect size = 0.45).

Safety and tolerability of SEP-363856 were generally similar to placebo

https://www.psychcongress.com/news/new-psychotropic-drug-schizophrenia-promising-early-testing
Sunovion Pharmaceuticals and PsychoGenics unveiled positive phase 2 results for a new schizophrenia treatment that does not bind to the brain’s dopamine receptors.

The placebo-controlled study met its primary endpoint, enrolling 245 hospitalized patients with acute worsening of schizophrenia and demonstrating improvements in a total syndrome scale over four weeks of daily treatment. Improvements were also seen in the overall severity of illness and psychopathology subscales.

https://www.fiercebiotech.com/biotech/sunovion-psychogenics-non-dopamine-schizophrenia-drug-meets-phase-2-endpoint
Spännande projekt, men ovissheten med hur effekten utövas är ett osäkerhetsmoment. Har nog aldrig läst om en sådan ovisshet. Fabrikanten påstår att "centrala effekter" har påvisats på patienter med schizofreni. Antagligen skedde det under första FAS I prövningen. Problemet med nya läkemedel är att effekten är djurtestad och därför osäker. Förr gav man möss eller råttor amfetamin, så de fick psykos och sedan testades antipsykotika effekten. Inte helt ett idealt test.